A Phase I Trial of GSK1120212 and GSK1120212 in Combination With Gemcitabine in Japanese Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Trametinib (Primary) ; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 13 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 17 May 2013 Planned end date changed from 1 Mar 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 17 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.